Clinical trials in Bilthoven – page 81

1 718 clinical trials in Bilthoven, The Netherlands across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in the NetherlandsKlinischOnderzoek.nl

Bilthoven at a glance

1 718

clinical trials

Research sites2

Quick filters

1 718 trials in Bilthoven

Open in trial search

Non-small cell lung cancer

Not recruiting

Efficacy of Cobolimab, Dostarlimab, and Docetaxel in Advanced Non-Small Cell Lung Cancer Post Anti-PD(L)1 Therapy and Chemotherapy

Registered drugNo placebo

Efficacy of Cobolimab, Dostarlimab, and Docetaxel in Advanced Non-Small Cell Lung Cancer Post Anti-PD(L)1 Therapy and Chemotherapy

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Cobolimab
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Systemic lupus erythematosus

Not recruiting

Evaluation of safety and efficacy of 19CP02 combined with cyclophosphamide and fludarabine phosphate in adults with treatment‑refractory active systemic lupus erythematosus

Registered drugNo placebo

Evaluation of safety and efficacy of 19CP02 combined with cyclophosphamide and fludarabine phosphate in adults with treatment‑refractory active systemic lupus erythematosus

Registered drugNo placebo

The Netherlands

Participants:18–64 years
Substances:Cyclophosphamide
Sponsor:Lakefront Biotherapeutics

Contact Research Centre

Study to evaluate the effects of brexanolone and lorazepam on the nervous system in healthy male participants using magnetic brain stimulation

Not recruiting

Registered drug

Study to evaluate the effects of brexanolone and lorazepam on the nervous system in healthy male participants using magnetic brain stimulation

Registered drug

The Netherlands

Participants:18–64 years · Healthy volunteers
Substances:Brexanolone
Sponsor:Sage Therapeutics Inc.

Contact Research Centre

Plasma cell myeloma

Not recruiting

Efficacy and Safety Evaluation of Belantamab Mafodotin Versus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients

Registered drugNo placebo

Efficacy and Safety Evaluation of Belantamab Mafodotin Versus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Belantamab Mafodotin
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Dermatitis atopic

Not recruiting

Safety and Tolerability of Topical Iodine (DLQ03) in Patients with Mild to Moderate Atopic Dermatitis Colonized with Staphylococcus aureus

Registered drug

Safety and Tolerability of Topical Iodine (DLQ03) in Patients with Mild to Moderate Atopic Dermatitis Colonized with Staphylococcus aureus

Registered drug

The Netherlands

Participants:18–64 years · 65+ years
Substances:Iodine
Sponsor:Dermaliq Therapeutics Inc.

Contact Research Centre

Transitional cell carcinoma metastatic

Not recruiting

Phase 1/2 Evaluation of Zilovertamab Vedotin in PD-1/L1 Refractory Locally Advanced or Metastatic Urothelial Carcinoma

Registered drugNo placebo

Phase 1/2 Evaluation of Zilovertamab Vedotin in PD-1/L1 Refractory Locally Advanced or Metastatic Urothelial Carcinoma

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Pembrolizumab
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Systemic lupus erythematosus

Not recruiting

Efficacy and Safety Evaluation of Litifilimab in Adults with Active Systemic Lupus Erythematosus on Standard Nonbiologic Lupus Care: A Phase 3 Randomized Controlled Trial

Investigational

Efficacy and Safety Evaluation of Litifilimab in Adults with Active Systemic Lupus Erythematosus on Standard Nonbiologic Lupus Care: A Phase 3 Randomized Controlled Trial

Investigational

The Netherlands

Participants:18–64 years · 65+ years
Substances:Litifilimab
Sponsor:Biogen Idec Research Limited

Contact Research Centre

Osteosarcoma

Not recruiting

Efficacy and Safety of Maintenance Cabozantinib Plus Best Supportive Care in Pediatric and AYA Patients with Unresectable Residual Osteosarcoma

Registered drugNo placebo

Efficacy and Safety of Maintenance Cabozantinib Plus Best Supportive Care in Pediatric and AYA Patients with Unresectable Residual Osteosarcoma

Registered drugNo placebo

The Netherlands

Participants:0–17 years · 18–64 years
Substances:Cabozantinib
Sponsor:Ipsen Innovation

Contact Research Centre

Hormone-dependent prostate cancer+1

Not recruiting

A Study of Mevrometostat and Enzalutamide for Men with Metastatic Castration-Sensitive Prostate Cancer Who Have Not Received Hormonal Therapy or Chemotherapy

Registered drug

A Study of Mevrometostat and Enzalutamide for Men with Metastatic Castration-Sensitive Prostate Cancer Who Have Not Received Hormonal Therapy or Chemotherapy

Registered drug

The Netherlands

Participants:18–64 years · 65+ years
Substances:Enzalutamide
Sponsor:Pfizer Inc.

Contact Research Centre

Dementia Alzheimer's type

Not recruiting

A study testing MK-1167 added to current treatment in patients with mild to moderate Alzheimer's disease dementia

Investigational

A study testing MK-1167 added to current treatment in patients with mild to moderate Alzheimer's disease dementia

Investigational

The Netherlands

Participants:18–64 years · 65+ years
Substances:MK-1167
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Gastric cancer+6

Not recruiting

A Study of CLDN6 CAR-T Cell Therapy With or Without CLDN6 RNA-LPX Vaccine in Patients With CLDN6-Positive Advanced Solid Tumors That Returned or Did Not Respond to Treatment

InvestigationalNo placebo

A Study of CLDN6 CAR-T Cell Therapy With or Without CLDN6 RNA-LPX Vaccine in Patients With CLDN6-Positive Advanced Solid Tumors That Returned or Did Not Respond to Treatment

InvestigationalNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Sponsor:BioNTech Cell & Gene Therapies GmbH

Contact Research Centre

Prostate cancer

Not recruiting

Study of xaluritamig compared to cabazitaxel or androgen receptor therapy for patients with metastatic castration-resistant prostate cancer

Registered drugNo placebo

Study of xaluritamig compared to cabazitaxel or androgen receptor therapy for patients with metastatic castration-resistant prostate cancer

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Abiraterone Acetate
Sponsor:Amgen Inc.

Contact Research Centre

Other cities in the Netherlands

The busiest research cities in the country

All 101 cities in the Netherlands

Clinical research in Bilthoven

What the registry says about research in the country

01 Infectious Disease Prevention

Research focusing on optimizing vaccine effectiveness against multiple infectious diseases, including studies on meningococcal disease and influenza in different age groups.

Meningococcal Disease Prevention
Influenza Vaccination Timing
Early Measles Protection

Novel approaches include investigating optimal vaccination timing and early immunization strategies for enhanced protection.

02 Oncology Research

Advanced studies in breast cancer treatment, examining innovative therapeutic combinations for hormone receptor-positive cases.

Hormone Receptor Positive Breast Cancer
CDK 4/6 Inhibition Therapy
Sequential Treatment Strategies

Investigations focus on optimizing treatment sequences to improve progression-free survival rates.

03 Surgical Interventions

Clinical research examining surgical treatments combined with antibiotic therapy for improved patient outcomes.

Perianal Abscess Management
Combined Treatment Approaches
Fistula Prevention

Studies aim to enhance surgical outcomes through innovative combination therapies.

Back to the Netherlands All countries